Is Using Antihypertensive Drugs before Arteriovenous Fistula Surgery Effective on Fistula Thrombosis in Patients with Hypertension?

Document Type : Original Article (s)

Authors

1 Professor, Department of Anesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The number of patients with end-stage renal disease (ESRD) and the need for hemodialysis (HD) has increased and they needed repeated intervention to maintain access patency. Care of hemodialysis patients has considerable economic burden on health care system. The effects of antihypertensive medications on arteriovenous fistula (AVF) thrombosis are not clearly explained. This study aimed to evaluate the effects of continuing and discontinuing use of antihypertensive medications in peri-operative time on arteriovenous fistula thrombosis.Methods: This was a clinical trial study on 60 patients with ESRD and hypertension, candidates for hemodialysis that divided into two groups. The case group received their antihypertensive drug before surgery and the control group did not receive. Systolic, diastolic, and mean arterial blood pressure and heart rate were evaluated before and during surgery; the incidence of thrombosis immediately, 24 hours, and one week after surgery was evaluated as well.Findings: Patients with mean age of 58.85 ± 14.95 years were participated that 78.4% of them were men. The mean systolic blood pressure was higher in control group but this difference was just statistically significant before surgery and at the start of administering local anesthesia. Just before surgery, the mean diastolic blood pressure and mean arterial blood pressure were higher in control group significantly. The number of thrombosis in case group was higher significantly than control group immediately (P = 0.03), 24 hours (P = 0.04), and one week (P =0.02) after the surgery.Conclusion: Using antihypertensive medications in patients, candidates for arteriovenous fistula, increased the risk of arteriovenous fistula thrombosis.

Keywords

References

  1. Schild AF. Maintaining vascular access: The management of hemodialysis arteriovenous grafts. J Vasc Access 2010; 11(2): 92-9.
  2. Bashar K, Zafar A, Elsheikh S, Healy DA, Clarke-Moloney M, Casserly L, et al. Predictive parameters of arteriovenous fistula functional maturation in a population of patients with end-stage renal disease. PLoS One 2015; 10(3): e0119958.
  3. Muchayi T, Salman L, Tamariz LJ, Asif A, Rizvi A, Lenz O, et al. A meta-analysis of randomized clinical trials assessing hemodialysis access thrombosis based on access flow monitoring: Where do we stand? Semin Dial 2015; 28(2): E23-E29.
  4. Wu CC, Jiang H, Cheng J, Zhao LF, Sheng KX, Chen JH. The outcome of the proximal radial artery arteriovenous fistula. J Vasc Surg 2015; 61(3): 802-8.
  5. Jackson RS, Sidawy AN, Amdur RL, Khetarpal A, Macsata RA. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access placement. J Vasc Surg 2011; 54(6): 1706-12.
  6. Jackson AJ, Coats P, Kingsmore DB. Pharmacotherapy to improve outcomes in vascular access surgery: A review of current treatment strategies. Nephrol Dial Transplant 2012; 27(5): 2005-16.
  7. Sajgure A, Choudhury A, Ahmed Z, Choudhury D. Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. Nephrol Dial Transplant 2007; 22(5): 1390-8.
  8. Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: A systematic review. J Vasc Surg 2003; 38(5): 1005-11.
  9. Heine GH, Ulrich C, Kohler H, Girndt M. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake? Am J Nephrol 2004; 24(4): 461-8.
  10. Doi S, Masaki T, Shigemoto K, Harada S, Yorioka N. Calcium channel antagonists reduce restenosis after percutaneous transluminal angioplasty of an arteriovenous fistula in hemodialysis patients. Ther Apher Dial 2008; 12(3): 232-6.
  11. Chen FA, Chien CC, Chen YW, Wu YT, Lin CC. Angiotensin Converting-Enzyme Inhibitors, Angiotensin Receptor Blockers, and Calcium Channel Blockers Are Associated with Prolonged Vascular Access Patency in Uremic Patients Undergoing Hemodialysis. PLoS One 2016; 11(11): e0166362.
  12. De ,Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, Sepiacci G, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 1996; 7(8): 1169-77.
  13. Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K. Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 2003; 42(5): 1000-12.
  14. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14(9): 2313-21.
  15. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45(5): 1477-83.
  16. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59(6): 2325-34.
Journal of Isfahan Medical School
Volume 35, Issue 446 - Serial Number 446
July and August 2017
Pages 1178-1184

Files

History

  • Receive Date: 30 December 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics